Document is current
Any future updates will be listed below
-
Authors
Smyth, Emily Nash https://orcid.org/0000-0003-0583-0882
Beyrer, Julie https://orcid.org/0000-0002-7331-2625
Saverno, Kimberly R. https://orcid.org/0000-0002-3421-3755
Hadden, Elizabeth
Abedtash, Hamed
DeLuca, Angelo
Lawrence, Garreth W. https://orcid.org/0000-0002-0919-787X
Rybowski, Sarah
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Accepted: 7 August 2022
First Online: 12 September 2022
Declarations
:
: This study was sponsored by Eli Lilly & Company.
: Emily Nash Smyth, Julie Beyrer, Hamed Abedtash, Angelo DeLuca, and Sarah Rybowski are employees and shareholders of Eli Lilly & Company; Garreth W. Lawrence is an employee of Eli Lilly & Company; Kimberly R. Saverno is a former employee and shareholder of Eli Lilly & Company; Elizabeth Hadden is an employee of DeLisle & Associates, Ltd.
: As the databases used in the study are fully de-identified and compliant with the HIPAA, this study was exempt from institutional review board approval.
: Not applicable.
: Not applicable.
: The data that support the findings of this study have been originated by IBM<sup>®</sup> MarketScan<sup>®</sup>. These de-identified data are only available through third-party license. As such, the authors cannot make these data publicly available due to data-use agreements. Other researchers can access these data by purchasing a license through IBM Watson Health. Interested individuals may consult for more information on accessing the MarketScan<sup>®</sup> Research Databases.
: Not applicable.
: All authors contributed to the study conception and design. Data analysis was performed by Julie Beyrer and Elizabeth Hadden. All authors drafted, reviewed, and edited the manuscript. All authors read and approved the final version of the manuscript.
